Faidon Magkos1, Labros S Sidossis. 1. Laboratory of Nutrition and Clinical Dietetics, Department of Nutrition and Dietetics, Harokopio University, 70 El. Venizelou Avenue, 17671 Athens, Greece.
Abstract
PURPOSE OF REVIEW: The purpose of this article is to briefly outline the methods that are currently available for the determination of very low density lipoprotein-triglyceride (VLDL-TG) kinetics in man in vivo. RECENT FINDINGS: A number of novel methodologies have been developed over the years for quantifying VLDL-TG production, clearance, and turnover rates. Besides the splanchnic arteriovenous balance technique, tracer methods with radioactive and, more recently, stable isotopes have been widely used. Most of the latter approaches utilize an isotopically labelled substrate, such as glycerol, fatty acid or acetate, which is eventually incorporated into a VLDL-TG moiety, and monitor the time course of change in specific activity or enrichment. A procedure of in vivo labelling of VLDL-TG with stable isotopes and use of the labelled VLDL-TG as a tracer has also been described in man. There is, however, considerable variability in estimates of VLDL-TG kinetics obtained by the various techniques, which cannot be readily attributed to normal physiological variation. Still, a large part of this discrepancy may be related to differences in VLDL-TG pool size within the normal range, which seem to account for approximately 40-50% of the total variance in VLDL-TG kinetics in both men and women. SUMMARY: Several methods are available for quantifying VLDL-TG kinetics in man in vivo, varying in the selection of tracer, mode of administration and sampling, and data analysis. These inherent features, along with different pool sizes, result in multifold variable estimations of VLDL-TG kinetic parameters.
PURPOSE OF REVIEW: The purpose of this article is to briefly outline the methods that are currently available for the determination of very low density lipoprotein-triglyceride (VLDL-TG) kinetics in man in vivo. RECENT FINDINGS: A number of novel methodologies have been developed over the years for quantifying VLDL-TG production, clearance, and turnover rates. Besides the splanchnic arteriovenous balance technique, tracer methods with radioactive and, more recently, stable isotopes have been widely used. Most of the latter approaches utilize an isotopically labelled substrate, such as glycerol, fatty acid or acetate, which is eventually incorporated into a VLDL-TG moiety, and monitor the time course of change in specific activity or enrichment. A procedure of in vivo labelling of VLDL-TG with stable isotopes and use of the labelled VLDL-TG as a tracer has also been described in man. There is, however, considerable variability in estimates of VLDL-TG kinetics obtained by the various techniques, which cannot be readily attributed to normal physiological variation. Still, a large part of this discrepancy may be related to differences in VLDL-TG pool size within the normal range, which seem to account for approximately 40-50% of the total variance in VLDL-TG kinetics in both men and women. SUMMARY: Several methods are available for quantifying VLDL-TG kinetics in man in vivo, varying in the selection of tracer, mode of administration and sampling, and data analysis. These inherent features, along with different pool sizes, result in multifold variable estimations of VLDL-TG kinetic parameters.
Authors: Oliver T Bruns; Harald Ittrich; Kersten Peldschus; Michael G Kaul; Ulrich I Tromsdorf; Joachim Lauterwasser; Marija S Nikolic; Birgit Mollwitz; Martin Merkel; Nadja C Bigall; Sameer Sapra; Rudolph Reimer; Heinz Hohenberg; Horst Weller; Alexander Eychmüller; Gerhard Adam; Ulrike Beisiegel; Joerg Heeren Journal: Nat Nanotechnol Date: 2009-01-25 Impact factor: 39.213
Authors: Demidmaa Tuvdendorj; Xiao-jun Zhang; David L Chinkes; Lijian Wang; Zhanpin Wu; Noe A Rodriguez; David N Herndon; Robert R Wolfe Journal: Metabolism Date: 2015-01-08 Impact factor: 8.694
Authors: Andrea S Cornford; Ariel L Barkan; Alexander Hinko; Jeffrey F Horowitz Journal: Am J Physiol Endocrinol Metab Date: 2012-09-25 Impact factor: 4.310
Authors: Daniël B van Schalkwijk; Albert A de Graaf; Ben van Ommen; Kees van Bochove; Patrick C N Rensen; Louis M Havekes; Niek C A van de Pas; Huub C J Hoefsloot; Jan van der Greef; Andreas P Freidig Journal: J Lipid Res Date: 2009-06-10 Impact factor: 5.922
Authors: Lars P Sørensen; Iben R Andersen; Esben Søndergaard; Lars C Gormsen; Ole Schmitz; Jens S Christiansen; Søren Nielsen Journal: Diabetes Date: 2010-09-21 Impact factor: 9.461
Authors: Lars P Sørensen; Esben Søndergaard; Birgitte Nellemann; Jens S Christiansen; Lars C Gormsen; Søren Nielsen Journal: Diabetes Date: 2011-08-01 Impact factor: 9.461